Month: September 2022

Looking forward to presenting at @Eyecelerator during this week’s annual meeting…

Looking forward to presenting at @Eyecelerator during this week’s annual meeting of the @aao_ophth! Now, #clinicaltrials involving suprachoroidal delivery include a tyrosine kinase inhibitor, a corticosteroid, a #genetherapy & a virus-like drug conjugate https://t.co/qgyOQb2YzJ Source by Thomas Ciulla, MD, MBA Return to main website.

RT @eyetubenet: Are you attending the #AAO2022 Annual Meeting?! Join us in-pers…

RT @eyetubenet: Are you attending the #AAO2022 Annual Meeting?! Join us in-person or virtually for a #CME Symposium. ‘Into the Suprachoroi… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Recent article @RetinalPhys: #Suprachoroidal Drug Delivery T…


RT @ThomasCiullaMD: Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xipere’s approval, SC #drugdelivery is cl…


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Our paper, “Longer-Term Anti-VEGF Therapy Outcomes in Neova…

RT @ThomasCiullaMD: Our paper, https://t.co/vztXKnKI4P “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO-Related M… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @JCRnEDITORS: Suprachoroidal delivery enables targeting, localization and dur…

RT @JCRnEDITORS: Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions. | Thomas A. Ciulla @… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ScienceCrisp: REVIEW “Advancements in ocular gene therapy delivery: vectors …


RT @ScienceCrisp: REVIEW “Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques…


Source by Thomas Ciulla, MD, MBA

Return to main website.

Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xi…

Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xipere’s approval, SC #drugdelivery is clinical reality. 4 therapies delivered SC are in #clinicaltrials: a corticosteroid, a TKI, a #genetherapy & a virus-like drug conjugate. https://t.co/iIkyKHNh4r Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Just published, “Suprachoroidal delivery enables targeting, …

RT @ThomasCiullaMD: Just published, “Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions”… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ModernRetina: WATCH: Acing the suprachoroidal injection for targeted drug de…


RT @ModernRetina: WATCH: Acing the suprachoroidal injection for targeted drug delivery
#Ophthalmology #retina

https://t.co/3zwxF2tMfP http…


Source by Thomas Ciulla, MD, MBA

Return to main website.

Our paper, “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, a…

Our paper, https://t.co/vztXKnKI4P “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO-Related Macular Edema” now appears in print, in this month’s Ophthalmology Retina. More effective & durable therapies are needed. #eyes #retina #diabetes https://t.co/aOsmK3A9fx Source by Thomas Ciulla, MD, MBA Return to main website.